{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:21:07Z","timestamp":1792495267829,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,7]]},"DOI":"10.7759\/cureus.38662","type":"journal-article","created":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T10:24:00Z","timestamp":1683455040000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Bempedoic Acid to Prevent Cardiovascular Events in Individuals at Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized-Control Trials"],"prefix":"10.7759","author":[{"given":"Gautham Varun","family":"Krishna Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Sai Harshabhargav","family":"Chenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Tirumandyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur Rehman","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005375","article-title":"Mortality from ischemic heart disease","volume":"12","author":"Nowbar AN","year":"2019","unstructured":"Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes. 2019, 12:e005375. 10.1161\/CIRCOUTCOMES.118.005375","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0clinical practice guidelines","volume":"73","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0clinical practice guidelines. J Am Coll Cardiol. 2019, 73:3168-209. 10.1016\/j.jacc.2018.11.002","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980-2000","volume":"356","author":"Ford ES","year":"2007","unstructured":"Ford ES, Ajani UA, Croft JB, et al.. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007, 356:2388-98. 10.1056\/NEJMsa053935","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone NJ","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al.. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014, 63:2889-934. 10.1016\/j.jacc.2013.11.002","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report","volume":"9","author":"Jacobson TA","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, et al.. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015, 9:129-69. 10.1016\/j.jacl.2015.02.003","journal-title":"J Clin Lipidol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints","volume":"70","author":"Rosenson RS","year":"2017","unstructured":"Rosenson RS, Baker S, Banach M, et al.. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017, 70:1290-301. 10.1016\/j.jacc.2017.07.752","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes ES","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al.. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015, 36:1012-22. 10.1093\/eurheartj\/ehv043","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky SL","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, et al.. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016, 7:13457. 10.1038\/ncomms13457","journal-title":"Nat Commun"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano RP","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, et al.. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017, 390:1962-71. 10.1016\/S0140-6736(17)32290-0","journal-title":"Lancet"},{"key":"ref10","unstructured":"Medscape. New lipid-lowering drug earns FDA approval. (2020). Accessed: April 11, 2023: https:\/\/www.medscape.com\/viewarticle\/925580\/."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-048893","article-title":"Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis","volume":"12","author":"Lin Y","year":"2022","unstructured":"Lin Y, Parco C, Karathanos A, et al.. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ Open. 2022, 12:e048893. 10.1136\/bmjopen-2021-048893","journal-title":"BMJ Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg AC","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ES, et al.. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019, 322:1780-8. 10.1001\/jama.2019.16585","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen SE","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al.. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023, 388:1353-64. 10.1056\/NEJMoa2215024","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray KK","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, et al.. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019, 380:1022-32. 10.1056\/NEJMoa1803917","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5603\/KP.a2019.0013","article-title":"Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials","volume":"77","author":"Wang X","year":"2019","unstructured":"Wang X, Luo S, Gan X, He C, Huang R. Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Kardiol Pol. 2019, 77:207-16. 10.5603\/KP.a2019.0013","journal-title":"Kardiol Pol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.050","article-title":"Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial","volume":"62","author":"Ballantyne CM","year":"2013","unstructured":"Ballantyne CM, Davidson MH, Macdougall DE, et al.. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013, 62:1154-62. 10.1016\/j.jacc.2013.05.050","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson PD","year":"2015","unstructured":"Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015, 9:295-304. 10.1016\/j.jacl.2015.03.003","journal-title":"J Clin Lipidol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar N","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, et al.. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010, 375:735-42. 10.1016\/S0140-6736(09)61965-6","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35395","article-title":"Bempedoic acid for lipid management in the Indian population: An expert opinion","volume":"15","author":"Hiremath J","year":"2023","unstructured":"Hiremath J, Mohan JC, Hazra P, et al.. Bempedoic acid for lipid management in the Indian population: An expert opinion. Cureus. 2023, 15:e35395. 10.7759\/cureus.35395","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14645","article-title":"Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials","volume":"24","author":"Leiter LA","year":"2022","unstructured":"Leiter LA, Banach M, Catapano AL, et al.. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab. 2022, 24:868-80. 10.1111\/dom.14645","journal-title":"Diabetes Obes Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108369","article-title":"Effect of bempedoic acid on new onset or worsening diabetes: A meta-analysis","volume":"168","author":"Masson W","year":"2020","unstructured":"Masson W, Lobo M, Lavalle-Cobo A, Masson G, Molinero G. Effect of bempedoic acid on new onset or worsening diabetes: A meta-analysis. Diabetes Res Clin Pract. 2020, 168:108369. 10.1016\/j.diabres.2020.108369","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/155870-efficacy-and-safety-of-bempedoic-acid-to-prevent-cardiovascular-events-in-individuals-at-risk-of-cardiovascular-diseases-a-meta-analysis-of-randomized-control-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:58:22Z","timestamp":1707508702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/155870-efficacy-and-safety-of-bempedoic-acid-to-prevent-cardiovascular-events-in-individuals-at-risk-of-cardiovascular-diseases-a-meta-analysis-of-randomized-control-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,7]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.38662","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,7]]}}}